TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7863857

Group type: EXPERIMENTAL
Intervention: ESWL
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PNL
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combined ESWL and PNL
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (ESWL)
Number of subjects: 48
Study: 2644108

Group type: EXPERIMENTAL
Intervention: Cefotetan (2 gm intravenously at the beginning of surgery)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Cefoxitin (1 gm intravenously at the beginning of surgery and after 3, 6, and 12 hours)
Number of subjects: 403
Study: 31119913

Group type: EXPERIMENTAL
Intervention: TECAR
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pressure therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (rehabilitation program only)
Number of subjects: 48
Study: 28399152

Group type: EXPERIMENTAL
Intervention: Psychoeducation programme (n = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual care (n = 10)
Number of subjects: 19
Study: 26188786

Group type: EXPERIMENTAL
Intervention: In situ repair
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tear completion repair
Number of subjects: 100
Study: 23864647

Group type: EXPERIMENTAL
Intervention: Phenytoin (184 mg once daily for 7 days post-delivery)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (zidovudine pre-delivery, single-dose nevirapine/zidovudine/lamivudine at delivery and zidovudine/lamivudine for 7 days post-delivery)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 72
Study: 21350434

Group type: EXPERIMENTAL
Intervention: Oral methylphenidate (MPH)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Food stimuli with MPH
Number of subjects: 18

Group type: COMPARATOR
Intervention: Food stimuli with Placebo
Number of subjects: 18
Study: 19386071

Group type: EXPERIMENTAL
Intervention: Bi-level positive airway pressure ventilation (BV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham ventilation (SV)
Number of subjects: 24
Study: 16809647

Group type: EXPERIMENTAL
Intervention: Water-soluble lubricant gel
Number of subjects: 70

Group type: COMPARATOR
Intervention: No gel (standard of care)
Number of subjects: 70
Study: 12518293

Group type: EXPERIMENTAL
Intervention: Ketamine (bolus 0.23 mg/kg; 0.5 mg/kg over 45 min to a maximum 1 hr)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (saline i.v.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketamine and Placebo
Number of subjects: 8
Study: 12020396

Group type: EXPERIMENTAL
Intervention: 5'‐DFUR administered orally for 6 months
Number of subjects: 1217

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1217
Study: 9583665

Group type: EXPERIMENTAL
Intervention: Music intervention (rock music) for a 23-minute session
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (sit and relax for 23 minutes)
Number of subjects: 14
Study: 8568186

Group type: EXPERIMENTAL
Intervention: Fetal pulse oximetry (Nellcor N-400)
Number of subjects: 0
Study: 2203555

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 1112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1112

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1112
Study: 75439

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 68
Study: 31283481

Group type: EXPERIMENTAL
Intervention: Passive Haptic Scenario (visual, auditory, and passive haptic) - N = 13
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Multisensory Scenario (visual, auditory, wind, passive haptic, vibration, and scent) - N = 12
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control Scenario (visual and auditory) - N = 12
Number of subjects: 37
Study: 29882727

Group type: EXPERIMENTAL
Intervention: e-prescription
Number of subjects: 95
Study: 27684037

Group type: EXPERIMENTAL
Intervention: Brief written materials (intervention group)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Genetic counseling session at a familial cancer clinic (usual-care group)
Number of subjects: 135
Study: 26044464

Group type: EXPERIMENTAL
Intervention: Nutritional supplement (150 kcal, 20 g whey protein, 800 IU vitamin D)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo drink (30 kcal, non-nutritive)
Number of subjects: 150
Study: 24776045

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stents
Number of subjects: 686

Group type: COMPARATOR
Intervention: Polymer-based paclitaxel-eluting stents
Number of subjects: 686
Study: 21670338

Group type: EXPERIMENTAL
Intervention: Digital grading of diabetic retinopathy severity
Number of subjects: 310

Group type: COMPARATOR
Intervention: Film grading of diabetic retinopathy severity
Number of subjects: 310
Study: 19565475

Group type: EXPERIMENTAL
Intervention: 5 mg CP-690,550 twice daily
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 15 mg CP-690,550 twice daily
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 30 mg CP-690,550 twice daily
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: All CP-690,550 treatment arms
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: 15 mg and 30 mg CP-690,550
Number of subjects: 264
Study: 17001661

Group type: EXPERIMENTAL
Intervention: Doxorubicin alone or combined with paclitaxel and/or cisplatin
Number of subjects: 1151
Study: 15302243

Group type: EXPERIMENTAL
Intervention: Early mobilisation using an exercise regime
Number of subjects: 108

Group type: COMPARATOR
Intervention: Soft collar treatment for 3 weeks followed by the same exercise regime
Number of subjects: 108
Study: 11404114

Group type: EXPERIMENTAL
Intervention: Hand-held dynamometry for measuring maximum isometric muscle force in boys and girls.
Number of subjects: 270
Study: 9436283

Group type: EXPERIMENTAL
Intervention: T1c tumors
Number of subjects: 51

Group type: COMPARATOR
Intervention: Non-T1c tumors with PSA < 4 ng/ml
Number of subjects: 51
Study: 8312586

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 257

Group type: COMPARATOR
Intervention: Not treated with tamoxifen
Number of subjects: 257
Study: 30244209

Group type: EXPERIMENTAL
Intervention: 2011 Accreditation Council for Graduate Medical Education resident duty hour rules
Number of subjects: 63

Group type: COMPARATOR
Intervention: More flexible intern shift length and number of hours off between shifts
Number of subjects: 63
Study: 27501614

Group type: EXPERIMENTAL
Intervention: Intra-Articular Infiltration (IA) with 15 mL of 0.25% bupivacaine into the knee joint and 5 mL infiltrated along the incision sites.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Femoral Nerve Block (FNB) with 20 mL of 0.25% bupivacaine under ultrasound guidance.
Number of subjects: 40
Study: 24853809

Group type: EXPERIMENTAL
Intervention: Insulin only (32%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Insulin and oral antidiabetics (OADs) (15%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: OADs only (27%)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: No drugs (26%)
Number of subjects: 100
Study: 23011325

Group type: EXPERIMENTAL
Intervention: Calcium‐containing preparation administrated orally for 1 to 3 months
Number of subjects: 78

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 78
Study: 20498618

Group type: EXPERIMENTAL
Intervention: Valsartan/hydrochlorothiazide (320/25 mg)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Hydrochlorothiazide plus amlodipine (25 mg and 10 mg)
Number of subjects: 412
Study: 18677236

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.4% polyethylene glycol/0.3% propylene glycol
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.0% carboxymethylcellulose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oil emulsion
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low viscosity carboxymethylcellulose
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Moderate viscosity hydroxypropylmethylcellulose-containing formulation
Number of subjects: 16
Study: 15886236

Group type: EXPERIMENTAL
Intervention: 1 microg ACTH stimulation in group B (hospitalized medical patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 250 microg ACTH stimulation in group B (hospitalized medical patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 250 microg ACTH stimulation in group C (patients undergoing coronary artery bypass grafting)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: ACTH stimulation in group C (surgical patients)
Number of subjects: 74

Group type: COMPARATOR
Intervention: 1 microg and 250 microg ACTH stimulation in groups A (ambulatory controls) and B (medical patients)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Diagnosis of relative adrenal insufficiency
Number of subjects: 74
Study: 12598280

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway Fastrach (ILM)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Trachlight lightwand (LW)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (LS)
Number of subjects: 150
Study: 10100273

Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome) - 60 mg/m2, intravenous infusion, once every 4 weeks, up to 600 mg/m2 cumulative dose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Liposomal daunorubicin (DaunoXome)
Number of subjects: 14
Study: 8775524

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty (PTCA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical strategy
Number of subjects: 100
Study: 1672392

Group type: EXPERIMENTAL
Intervention: Intramuscular magnesium sulphate every week for 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 6512802

Group type: EXPERIMENTAL
Intervention: Intravenous Augmentin (amoxycillin and clavulanic acid)
Number of subjects: 0
Study: 30475777

Group type: EXPERIMENTAL
Intervention: Esophageal pressure titration PEEP (n = 12)
Number of subjects: 23

Group type: COMPARATOR
Intervention: ARDSNet (PEEP-FiO2 table) titration PEEP (n = 11)
Number of subjects: 23
Study: 29548270

Group type: EXPERIMENTAL
Intervention: Movement-Pattern Training (MPT)
Number of subjects: 28
Study: 26973269

Group type: EXPERIMENTAL
Intervention: Early rehabilitation therapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (rehabilitation therapy after leaving ICU)
Number of subjects: 106
Study: 24738933

Group type: EXPERIMENTAL
Intervention: Vitamin B1 100 mg daily for three months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 22343669

Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (PN) during HSCT
Number of subjects: 26
Study: 19188102

Group type: EXPERIMENTAL
Intervention: Self-perceived weight status
Number of subjects: 899
Study: 17999764

Group type: EXPERIMENTAL
Intervention: Assessment of vascular risk factors including blood pressure, waist circumference, body mass index (BMI), ankle brachial index (ABI), and total and HDL cholesterol.
Number of subjects: 402
Study: 15257032

Group type: EXPERIMENTAL
Intervention: FK778 high-level group (2 x 600 mg/day FK778 followed by 150 mg/day)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: FK778 low-level group (1 x 600 mg/day FK778 followed by 75 mg/day)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: FK778 high-level group
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: FK778 low-level group
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: FK778 treatment
Number of subjects: 149
Study: 11668380

Group type: EXPERIMENTAL
Intervention: Group I (hemodilution with autologous blood predonations)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Group II (control with homologous blood transfusion)
Number of subjects: 22
Study: 9851959

Group type: EXPERIMENTAL
Intervention: Clomipramine (25 mg administered intravenously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tilt test
Number of subjects: 20
Study: 7988129

Group type: EXPERIMENTAL
Intervention: Pressure-triggered synchronous intermittent mandatory ventilation at 60% of the assist-control rate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flow-triggered synchronous intermittent mandatory ventilation at 40% of the assist-control rate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pressure-triggered synchronous intermittent mandatory ventilation at 20% of the assist-control rate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pressure-triggered synchronous intermittent mandatory ventilation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Flow-triggered synchronous intermittent mandatory ventilation
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Pressure-time product
Number of subjects: 8
Study: 2692315

Group type: EXPERIMENTAL
Intervention: 100 mg ASS daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: 500 mg ASS daily
Number of subjects: 20
Study: 4601523

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth (De-Nol)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31722446

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg twice daily
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Mirogabalin 10 or 15 mg twice daily
Number of subjects: 214
Study: 31004141

Group type: EXPERIMENTAL
Intervention: Standard of care (SOC) plus 48-hour positive airway pressure (PAP) therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 21
Study: 28581341

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention including education for prescribers, auditing on metabolic monitoring, and feedback to mental health center leaders.
Number of subjects: 0
Study: 26727829

Group type: EXPERIMENTAL
Intervention: Optimal correction of anemia with Erythropoietin β (Recormon®)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Suboptimal correction of anemia (not achieving target hemoglobin)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Erythropoietin β (Recormon®)
Number of subjects: 50
Study: 23495916

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA) with iCa titrated to 0.8-1.0 mm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA) with iCa titrated to 1.1-1.4 mm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation (RCA)
Number of subjects: 15
Study: 20920136

Group type: EXPERIMENTAL
Intervention: Spray catheter instillation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard injection through the working channel
Number of subjects: 40
Study: 19564665

Group type: EXPERIMENTAL
Intervention: Triaxial accelerometer (RT3) wear time defined as 8 or more hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normalization of data to a 12-hour day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restricting MVPA to activities occurring in bouts of 10 minutes or longer
Number of subjects: 0
Study: 17491172

Group type: EXPERIMENTAL
Intervention: Bupropion plus counseling plus access to CHESS SCRP (12 weeks)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Bupropion plus counseling
Number of subjects: 284
Study: 15636571

Group type: EXPERIMENTAL
Intervention: Single-level cervical arthroplasty with Bryan cervical artificial disc
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Two-level cervical arthroplasty with Bryan cervical artificial disc
Number of subjects: 13
Study: 11543752

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Acetaminophen plus codeine
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study: 9605375

Group type: EXPERIMENTAL
Intervention: Oxycodone 30 microg/kg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Morphine 45 microg/kg
Number of subjects: 50
Study: 8091435

Group type: EXPERIMENTAL
Intervention: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL)
Number of subjects: 14916

Group type: EXPERIMENTAL
Intervention: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL) in normotensive subjects
Number of subjects: 14916

Group type: EXPERIMENTAL
Intervention: High plasma levels of homocyst(e)ine (> 12.7 nmol/mL) in men 60 years or younger
Number of subjects: 14916

Group type: COMPARATOR
Intervention: Control subjects with lower homocyst(e)ine levels (bottom 80%)
Number of subjects: 14916
Study: 3053207

Group type: EXPERIMENTAL
Intervention: cisplatin 100 mg/m2 with cyclophosphamide 600 mg/m2
Number of subjects: 60

Group type: COMPARATOR
Intervention: carboplatin 300 mg/m2 with cyclophosphamide 600 mg/m2
Number of subjects: 60

Group type: COMPARATOR
Intervention: iproplatin 240 mg/m2 with cyclophosphamide 600 mg/m2
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cyclophosphamide/CHIP combination
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: cyclophosphamide/CBDCA combination
Number of subjects: 60
Study: 240979

Group type: EXPERIMENTAL
Intervention: Drug group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 31741562

Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (LIA) with levobupivacaine
Number of subjects: 60
Study: 29789607

Group type: EXPERIMENTAL
Intervention: Microspirometry (MI) using COPD-6® microspirometers
Number of subjects: 416

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 416
Study: 27112712

Group type: COMPARATOR
Intervention: Pedicled single internal thoracic artery
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Pedicled bilateral internal thoracic artery
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Skeletonized bilateral internal thoracic artery
Number of subjects: 2056

Group type: EXPERIMENTAL
Intervention: Skeletonized single internal thoracic artery
Number of subjects: 2056
Study: 24737141

Group type: EXPERIMENTAL
Intervention: Clinpro fissure sealant
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fuji VII fissure sealant
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Conventional fissure sealant technique (CST)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Enameloplasty sealant technique (EST)
Number of subjects: 80
Study: 22739107

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) for 60 min
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (nonstimulated leg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 6
Study: 20056926

Group type: EXPERIMENTAL
Intervention: Hemicraniectomy for malignant middle cerebral artery infarction
Number of subjects: 27
Study: 16874485

Group type: EXPERIMENTAL
Intervention: autologous TIL plus IL-2
Number of subjects: 88

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 88
Study: 15762943

Group type: EXPERIMENTAL
Intervention: Number-word sequence skill
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solving doubles problems (e.g., 2 + 2 = ?)
Number of subjects: 0
Study: 12168783

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel (HA gel)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10341825

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 8564096

Group type: EXPERIMENTAL
Intervention: Prednisolone (0.6 mg/kg/d)
Number of subjects: 18
Study: 2405996

Group type: EXPERIMENTAL
Intervention: Improved disease‐free survival of poor‐prognosis subgroups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improved sanctuary therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shortening of therapy duration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salvage of relapsed patients with better chemotherapy regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone marrow transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardization of staging systems
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reliable in vitro tests of chemosensitivity and chemoresistance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitation of residual leukemia after remission induction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of drug‐resistant clones of cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delivery of optimum therapy and supportive care
Number of subjects: 0
Study: 7238342

Group type: EXPERIMENTAL
Intervention: Intratracheal administration of gentamicin (40 mg, undiluted, 6-hourly)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 20
Study: 31234886

Group type: EXPERIMENTAL
Intervention: Preoperative short-course radiotherapy (SCRT, 5 × 5 Gy) plus FOLFOX4
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-course oxaliplatin and bolus of fluorouracil based preoperative long-course chemoradiotherapy (LCCRT, 50.4 Gy in 28 fractions)
Number of subjects: 0
Study: 28840379

Group type: EXPERIMENTAL
Intervention: Exercise + CTM
Number of subjects: 40

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 40
Study: 26308176

Group type: EXPERIMENTAL
Intervention: favipiravir 1,200 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: favipiravir 2,400 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: moxifloxacin 400 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study: 23229165

Group type: EXPERIMENTAL
Intervention: No water removal (NWR)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Water removal (WR)
Number of subjects: 56
Study: 23304688

Group type: EXPERIMENTAL
Intervention: Immediate loading of single implants (non-occlusal temporary crown within 24 hours)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed loading of single implants (definitive crown 4 to 5 months later)
Number of subjects: 20
Study: 19477488

Group type: EXPERIMENTAL
Intervention: Parnaparin 12,800 IU for 7 days followed by 6,400 IU for a total of 3 months
Number of subjects: 67

Group type: COMPARATOR
Intervention: Aspirin 100 mg/day for 3 months
Number of subjects: 67
Study: 17509947

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 7665

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7665
Study: 16094585

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol 50 mg
Number of subjects: 72